Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01223027




Registration number
NCT01223027
Ethics application status
Date submitted
30/09/2010
Date registered
18/10/2010
Date last updated
7/12/2015

Titles & IDs
Public title
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Scientific title
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Secondary ID [1] 0 0
2009-015459-25
Secondary ID [2] 0 0
CTKI258A2302
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Renal Cell Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dovitinib
Treatment: Drugs - Sorafenib

Experimental: Dovitinib + best supportive care (BSC) - Patients randomized to the dovitinib treatment arm received 500 mg of dovitinib orally on 5 days on/2 days off dosing schedule.

Active comparator: Sorafenib + BSC - Patients in the sorafenib control arm received400 mg of sorafenib (2 x 200 mg tablets) orally taken twice daily.


Treatment: Drugs: Dovitinib
Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.

Treatment: Drugs: Sorafenib
Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) Per Independent Central Radiology Review
Timepoint [1] 0 0
Until disease progression or discontinuation of treatment due to unacceptable toxicity up to 30-Jun-2014 (discontinuation)
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
until at least 386 deaths are documented in the clinical database.
Secondary outcome [2] 0 0
Progression Free Survival (PFS) Per Investigator's Radiology Review
Timepoint [2] 0 0
Until disease progression or discontinuation of treatment due to unacceptable toxicity
Secondary outcome [3] 0 0
Percentage of Participants With Overall Response Rate (ORR) by Central Radiology Review
Timepoint [3] 0 0
Until disease progression or discontinuation of treatment due to unacceptable toxicity
Secondary outcome [4] 0 0
Time to Definitive Worsening of Karnofsky Performance Status (KPS)
Timepoint [4] 0 0
from date of randomization to the date of definitive worsening of KPS or to the date of death whichever occurred earlier
Secondary outcome [5] 0 0
Patient-reported Outcomes (PROs): Time to Deterioration of Functional Assessment of Cancer Therapy-Kidney Symptom Index, Disease Related Symptoms (FKSI-DRS) by at Least 2 Scores
Timepoint [5] 0 0
from date of randomization, at least 2 score units
Secondary outcome [6] 0 0
Patient-reported Outcomes (PROs): Time to Definitive Deterioration of the Physical Functioning (PF) Scale of EORTC QLQ-C30 by at Least 10%
Timepoint [6] 0 0
from date of randomization
Secondary outcome [7] 0 0
Patient-reported Outcomes (PROs): Time to Definitive Deterioration of the Quality of Life (QoL) Scale Scores of EORTC QLQ-C30 by at Least 10%
Timepoint [7] 0 0
from date of randomization
Secondary outcome [8] 0 0
Pre-dose Concentration in Plasma in Dovitinib
Timepoint [8] 0 0
Week 2 Day 5, Week 4 Day 5, Week 6 Day 5

Eligibility
Key inclusion criteria
* Patients with metastatic renal cell carcinoma (mRCC) with histological or cytological confirmation of clear cell carcinoma or a component of clear cell
* Patients must have received one and only one prior VEGF-targeted therapy and one and only one prior mTOR inhibitor therapy in the metastatic setting. One VEGF targeted therapy (e.g. sunitinib, or pazopanib, or axitinib, or tivozanib or bevacizumab) and one prior mTOR inhibitor therapy (everolimus, or temsirolimus or ridaforolimus)
* Prior cytokines therapy and prior vaccines in the adjuvant setting is permitted.
* Patients must have had disease progression on or within 6 months of stopping the last therapy.
* Patients must have at least one measurable lesion at baseline (by RECIST Criteria Guidelines v1.1) assessed by Computer Tomography (CT) Scan or Magnetic Resonance Imaging (MRI).
* Karnofsky performance status = 70%
* Patients must have the following laboratory values:

* Absolute Neutrophil Count (ANC) = 1.5 x 109/L
* Platelets = 100 x 109/L
* Hemoglobin (Hgb) > 9 g/dL
* Serum total bilirubin: = 1.5 x ULN
* ALT and AST = 3.0 x ULN (Patients with known liver metastases: AST and ALT = 5.0 x ULN)
* Serum creatinine = 1.5 x ULN
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients who have previously received sorafenib therapy in the neoadjuvant, adjuvant or metastatic setting.
* Patients who have previously received Dovitinib or brivanib in the neoadjuvant, adjuvant or metastatic setting.
* Patients with brain metastases. Radiological imaging (e.g. CT or MRI scan) of the brain is required at screening/baseline
* Patients with another primary malignancy within 3 years prior to starting study treatment, with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma or non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix
* Patients who have received the last administration of an anticancer targeted small molecule therapy = 2 weeks prior to starting study treatment (e.g. sunitinib, pazopanib, axitinib, everolimus, temsirolimus), or who have not recovered from the side effects of such therapy
* Patients who have received the last administration of nitrosurea or mitomycin-C = 6 weeks prior to starting study treatment, or who have not recovered from the side effects of such therapy
* Patients who have undergone major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) = 4 weeks prior to starting study treatment or who have not recovered from side effects of such therapy
* Patients with a history of pulmonary embolism (PE), or untreated deep venous thrombosis (DVT) within the past 6 months
* Patients with concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study

Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/06/2014
Sample size
Target
Accrual to date
Final
564
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - St. Leonards
Recruitment hospital [2] 0 0
Novartis Investigative Site - Westmead
Recruitment hospital [3] 0 0
Novartis Investigative Site - South Brisbane
Recruitment hospital [4] 0 0
Novartis Investigative Site - Woodville
Recruitment hospital [5] 0 0
Novartis Investigative Site - Footscray
Recruitment hospital [6] 0 0
Novartis Investigative Site - Heidelberg
Recruitment postcode(s) [1] 0 0
2065 - St. Leonards
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
5011 - Woodville
Recruitment postcode(s) [5] 0 0
3011 - Footscray
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Hawaii
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Utah
Country [20] 0 0
United States of America
State/province [20] 0 0
Virginia
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
Argentina
State/province [22] 0 0
Sante Fe
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Austria
State/province [24] 0 0
Linz
Country [25] 0 0
Austria
State/province [25] 0 0
Wien
Country [26] 0 0
Belgium
State/province [26] 0 0
Bruxelles
Country [27] 0 0
Belgium
State/province [27] 0 0
Gent
Country [28] 0 0
Belgium
State/province [28] 0 0
Leuven
Country [29] 0 0
Belgium
State/province [29] 0 0
Liège
Country [30] 0 0
Brazil
State/province [30] 0 0
RS
Country [31] 0 0
Canada
State/province [31] 0 0
Alberta
Country [32] 0 0
Canada
State/province [32] 0 0
British Columbia
Country [33] 0 0
Canada
State/province [33] 0 0
Nova Scotia
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Canada
State/province [36] 0 0
Saskatchewan
Country [37] 0 0
Colombia
State/province [37] 0 0
Bogota
Country [38] 0 0
Czech Republic
State/province [38] 0 0
Brno
Country [39] 0 0
Czech Republic
State/province [39] 0 0
Olomouc
Country [40] 0 0
Czech Republic
State/province [40] 0 0
Praha 5
Country [41] 0 0
France
State/province [41] 0 0
Besancon Cedex
Country [42] 0 0
France
State/province [42] 0 0
Bordeaux Cedex
Country [43] 0 0
France
State/province [43] 0 0
Caen Cedex
Country [44] 0 0
France
State/province [44] 0 0
Clermont-Ferrand
Country [45] 0 0
France
State/province [45] 0 0
Grenoble
Country [46] 0 0
France
State/province [46] 0 0
Lyon Cedex
Country [47] 0 0
France
State/province [47] 0 0
Marseille
Country [48] 0 0
France
State/province [48] 0 0
Nice Cedex 2
Country [49] 0 0
France
State/province [49] 0 0
Paris Cedex 13
Country [50] 0 0
France
State/province [50] 0 0
Paris
Country [51] 0 0
France
State/province [51] 0 0
Rennes Cedex
Country [52] 0 0
France
State/province [52] 0 0
Saint Priest en Jarez Cedex
Country [53] 0 0
France
State/province [53] 0 0
Saint-Herblain Cédex
Country [54] 0 0
France
State/province [54] 0 0
Strasbourg Cedex
Country [55] 0 0
France
State/province [55] 0 0
Suresnes
Country [56] 0 0
France
State/province [56] 0 0
Toulouse Cedex 9
Country [57] 0 0
France
State/province [57] 0 0
Vandoeuvre-Les-Nancy Cede
Country [58] 0 0
France
State/province [58] 0 0
Villejuif Cedex
Country [59] 0 0
Germany
State/province [59] 0 0
Aschaffenburg
Country [60] 0 0
Germany
State/province [60] 0 0
Berlin
Country [61] 0 0
Germany
State/province [61] 0 0
Chemnitz
Country [62] 0 0
Germany
State/province [62] 0 0
Erlangen
Country [63] 0 0
Germany
State/province [63] 0 0
Greifswald
Country [64] 0 0
Germany
State/province [64] 0 0
Hamburg
Country [65] 0 0
Germany
State/province [65] 0 0
Hannover
Country [66] 0 0
Germany
State/province [66] 0 0
Heidelberg
Country [67] 0 0
Germany
State/province [67] 0 0
Jena
Country [68] 0 0
Germany
State/province [68] 0 0
Leipzig
Country [69] 0 0
Germany
State/province [69] 0 0
Marburg
Country [70] 0 0
Germany
State/province [70] 0 0
Muenster
Country [71] 0 0
Germany
State/province [71] 0 0
München
Country [72] 0 0
Germany
State/province [72] 0 0
Nuernberg
Country [73] 0 0
Germany
State/province [73] 0 0
Ulm
Country [74] 0 0
Germany
State/province [74] 0 0
Weiden
Country [75] 0 0
Greece
State/province [75] 0 0
GR
Country [76] 0 0
Greece
State/province [76] 0 0
Athens
Country [77] 0 0
Hungary
State/province [77] 0 0
Budapest
Country [78] 0 0
Hungary
State/province [78] 0 0
Debrecen
Country [79] 0 0
Hungary
State/province [79] 0 0
Pecs
Country [80] 0 0
Hungary
State/province [80] 0 0
Szolnok
Country [81] 0 0
Israel
State/province [81] 0 0
Petach Tikva
Country [82] 0 0
Israel
State/province [82] 0 0
Ramat Gan
Country [83] 0 0
Israel
State/province [83] 0 0
Zrifin
Country [84] 0 0
Italy
State/province [84] 0 0
AR
Country [85] 0 0
Italy
State/province [85] 0 0
CR
Country [86] 0 0
Italy
State/province [86] 0 0
FC
Country [87] 0 0
Italy
State/province [87] 0 0
MI
Country [88] 0 0
Italy
State/province [88] 0 0
MO
Country [89] 0 0
Italy
State/province [89] 0 0
PV
Country [90] 0 0
Italy
State/province [90] 0 0
RM
Country [91] 0 0
Italy
State/province [91] 0 0
TO
Country [92] 0 0
Italy
State/province [92] 0 0
Napoli
Country [93] 0 0
Japan
State/province [93] 0 0
Aichi
Country [94] 0 0
Japan
State/province [94] 0 0
Ehime
Country [95] 0 0
Japan
State/province [95] 0 0
Fukuoka
Country [96] 0 0
Japan
State/province [96] 0 0
Hiroshima
Country [97] 0 0
Japan
State/province [97] 0 0
Hokkaido
Country [98] 0 0
Japan
State/province [98] 0 0
Hyogo
Country [99] 0 0
Japan
State/province [99] 0 0
Kanagawa
Country [100] 0 0
Japan
State/province [100] 0 0
Kyoto
Country [101] 0 0
Japan
State/province [101] 0 0
Nagano
Country [102] 0 0
Japan
State/province [102] 0 0
Osaka
Country [103] 0 0
Japan
State/province [103] 0 0
Saitama
Country [104] 0 0
Japan
State/province [104] 0 0
Tokyo
Country [105] 0 0
Japan
State/province [105] 0 0
Chiba
Country [106] 0 0
Japan
State/province [106] 0 0
Yamagata
Country [107] 0 0
Korea, Republic of
State/province [107] 0 0
Korea
Country [108] 0 0
Netherlands
State/province [108] 0 0
KR
Country [109] 0 0
Netherlands
State/province [109] 0 0
Amsterdam
Country [110] 0 0
Netherlands
State/province [110] 0 0
Breda
Country [111] 0 0
Netherlands
State/province [111] 0 0
Dordrecht
Country [112] 0 0
Netherlands
State/province [112] 0 0
Maastricht
Country [113] 0 0
Netherlands
State/province [113] 0 0
Rotterdam
Country [114] 0 0
Norway
State/province [114] 0 0
Bergen
Country [115] 0 0
Norway
State/province [115] 0 0
Ålesund
Country [116] 0 0
Poland
State/province [116] 0 0
Warszawa
Country [117] 0 0
Saudi Arabia
State/province [117] 0 0
Riyadh
Country [118] 0 0
Slovakia
State/province [118] 0 0
Slovak Republic
Country [119] 0 0
Spain
State/province [119] 0 0
Andalucia
Country [120] 0 0
Spain
State/province [120] 0 0
Asturias
Country [121] 0 0
Spain
State/province [121] 0 0
Barcelona
Country [122] 0 0
Spain
State/province [122] 0 0
Catalunya
Country [123] 0 0
Spain
State/province [123] 0 0
Comunidad Valenciana
Country [124] 0 0
Spain
State/province [124] 0 0
Galicia
Country [125] 0 0
Spain
State/province [125] 0 0
Islas Baleares
Country [126] 0 0
Spain
State/province [126] 0 0
Las Palmas de Gran Canaria
Country [127] 0 0
Spain
State/province [127] 0 0
Madrid
Country [128] 0 0
Spain
State/province [128] 0 0
Navarra
Country [129] 0 0
Sweden
State/province [129] 0 0
Stockholm
Country [130] 0 0
Sweden
State/province [130] 0 0
Sundsvall
Country [131] 0 0
Sweden
State/province [131] 0 0
Umeå
Country [132] 0 0
Sweden
State/province [132] 0 0
Uppsala
Country [133] 0 0
Switzerland
State/province [133] 0 0
St. Gallen
Country [134] 0 0
Thailand
State/province [134] 0 0
Bangkok
Country [135] 0 0
United Kingdom
State/province [135] 0 0
Avon
Country [136] 0 0
United Kingdom
State/province [136] 0 0
Middlesex
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Colchester
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Leicester
Country [139] 0 0
United Kingdom
State/province [139] 0 0
London
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Manchester
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.
Trial website
https://clinicaltrials.gov/study/NCT01223027
Trial related presentations / publications
Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grunwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Mar;15(3):286-96. doi: 10.1016/S1470-2045(14)70030-0. Epub 2014 Feb 17.
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01223027